Nuvation Bio Inc (NUVB) FinancialsNUVBFinancialNuvation Bio Inc

Evaluating the bottom line, Nuvation Bio Inc. maintains a gross margin of 70.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -161.06%, while the net margin is -198.31%. These profitability ratios, combined with a Return on Equity (ROE) of -47.81%, provide a clear picture of how effectively NUVB converts its operational activities into shareholder value.

In the context of the broader market, NUVB competes directly with industry leaders such as RAPP and KOD. With a market capitalization of $2.18B, it holds a significant position in the sector. When comparing efficiency, NUVB's gross margin of 70.11% stands against RAPP's 100.00% and KOD's N/A. Such benchmarking helps identify whether Nuvation Bio Inc. is trading at a premium or discount relative to its financial performance.

Nuvation Bio has demonstrated substantial revenue growth, with Q1 2026 revenue at $83.2 million and a gross margin of 92.80%. However, it still faces challenges with net income, which was negative at -$62.84 million in Q2 2026.